Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
API, approach, ASU, depict, Endo, equitable, error, FASB, fertile, greatest, Gregory, highest, incremental, midst, MiNE, overweight, PLC, redesign, retrospective, simplified, stipulated, UPM, User, Variable, week, withdrawn
Removed:
alternate, ANDERSEN, ARTHUR, asserted, auditing, Auxilium, BioVectra, building, carrying, collectively, conserve, COPY, devoting, Diagnostic, differentiated, enterprise, explained, expressed, frequency, impairment, intrinsic, Ladenburg, lesser, library, ofProellex, operated, put, QTRX, recoverable, REISSUED, salary, supplier, Thalmann, THUR, transition, undergo, undiscounted, unqualified, utilizing, viable, Zonagen
Filing tables
Filing exhibits
Related press release
Royalty Pharma similar filings
Filing view
External links
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File Nos. 333-197253, 333-163510, 333-167409, 333-184159 and 333-184471) and Form S-8 (File Nos. 333-200370, 333-39413, 333-58542, 333-122343 and 333-175641) of Repros Therapeutics Inc. of our report dated March 16, 2015 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Houston, Texas
March 16, 2015